{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:22Z","timestamp":1761059602521},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T00:00:00Z","timestamp":1381190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s11899-013-0178-x","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T09:10:21Z","timestamp":1381137021000},"page":"325-332","source":"Crossref","is-referenced-by-count":12,"title":["The New Landscape of Therapy for Myelofibrosis"],"prefix":"10.1007","volume":"8","author":[{"given":"Krisstina","family":"Gowin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Emanuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,8]]},"reference":[{"key":"178_CR1","doi-asserted-by":"crossref","unstructured":"Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007.","DOI":"10.1016\/j.leukres.2006.12.002"},{"issue":"12","key":"178_CR2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","volume":"11","author":"C James","year":"2005","unstructured":"\u2022\u2022 James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005;11(12):546\u201354. The first description of JAK2-V617F in MPNs, a watershed both in therapeutic targeting and well as pathogenetic insight.","journal-title":"Trends Mol Med"},{"key":"178_CR3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Soon-Siong T, Tiedt R, Passweg JR, et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New Engl J Med. 2005;352:1779\u201390.","journal-title":"New Engl J Med"},{"issue":"5","key":"178_CR4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.hoc.2012.07.006","volume":"26","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012;26(5):1053\u201364. doi: 10.1016\/j.hoc.2012.07.006 .","journal-title":"Hematol Oncol Clin North Am"},{"issue":"22","key":"178_CR5","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289\u2013301. doi: 10.1056\/NEJMoa0810069 .","journal-title":"N Engl J Med"},{"issue":"6","key":"178_CR6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","volume":"116","author":"ST Oh","year":"2010","unstructured":"Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs Jr KD, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(6):988\u201392. doi: 10.1182\/blood-2010-02-270108 .","journal-title":"Blood"},{"issue":"7","key":"178_CR7","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.","journal-title":"PLoS Med"},{"issue":"9","key":"178_CR8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12(9):599\u2013612. doi: 10.1038\/nrc3343 .","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"178_CR9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128\u201338. doi: 10.1038\/leu.2010.69 .","journal-title":"Leukemia"},{"issue":"7","key":"178_CR10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723\u201335. doi: 10.1182\/blood-2011-02-292102 .","journal-title":"Blood"},{"issue":"1","key":"178_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11899-011-0105-y","volume":"7","author":"SJ Zhang","year":"2012","unstructured":"Zhang SJ, Abdel-Wahab O. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2012;7(1):34\u201342. doi: 10.1007\/s11899-011-0105-y .","journal-title":"Curr Hematol Malig Rep"},{"key":"178_CR12","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009. doi: 10.1182\/blood-2009-03-209262 .","journal-title":"Blood"},{"key":"178_CR13","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, et al. Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res. 2013. doi: 10.1016\/j.leukres.2013.04.017 .","journal-title":"Leuk Res"},{"issue":"13","key":"178_CR14","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901. doi: 10.1182\/blood-2008-07-170449 .","journal-title":"Blood"},{"issue":"33","key":"178_CR15","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098\u2013103. doi: 10.1200\/JCO.2012.42.3863 .","journal-title":"J Clin Oncol"},{"issue":"4","key":"178_CR16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood. 2010;115(4):778\u201382. doi: 10.1182\/blood-2009-08-238956 .","journal-title":"Blood"},{"issue":"2","key":"178_CR17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401\u20138. doi: 10.1182\/blood-2011-01-328955 .","journal-title":"Blood"},{"issue":"21","key":"178_CR18","first-page":"1731","volume":"120","author":"HL Geyer","year":"2012","unstructured":"Geyer HL, Dueck AC, Emanuel RM, Kiladjian J-J, Slot S, Zweegman S, et al. The myelofibrosis symptom burden (MF-SB): An international phenotypic cluster analysis of 329 patients. ASH Annual Meeting Abstracts. 2012;120(21):1731.","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9","key":"178_CR19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138. doi: 10.1182\/blood-2009-09-245837 .","journal-title":"Blood"},{"issue":"4","key":"178_CR20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"178_CR21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10428194.2012.710905","volume":"54","author":"RA Mesa","year":"2013","unstructured":"Mesa RA. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma. 2013;54(2):242\u201351. doi: 10.3109\/10428194.2012.710905 .","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"178_CR22","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation. Blood. 2009;114(26):5264\u201370. doi: 10.1182\/blood-2009-07-234880 .","journal-title":"Blood"},{"key":"178_CR23","doi-asserted-by":"crossref","unstructured":"Fauble V, Leis J, Mesa R. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leukemia. 2012(Supplement 2012):S2\u2013S7","DOI":"10.1038\/leusup.2012.2"},{"issue":"6","key":"178_CR24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","volume":"129","author":"F Cervantes","year":"2005","unstructured":"Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients. Br J Haematol. 2005;129(6):771\u20135.","journal-title":"Br J Haematol"},{"issue":"3","key":"178_CR25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000097463","volume":"117","author":"SN Tsiara","year":"2007","unstructured":"Tsiara SN, Chaidos A, Bourantas LK, Kapsali HD, Bourantas KL. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol. 2007;117(3):156\u201361. doi: 10.1159\/000097463 .","journal-title":"Acta Haematol"},{"issue":"2","key":"178_CR26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","volume":"83","author":"J Huang","year":"2009","unstructured":"Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol. 2009;83(2):154\u20135. doi: 10.1111\/j.1600-0609.2009.01266.x .","journal-title":"Eur J Haematol"},{"issue":"1","key":"178_CR27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajh.21892","volume":"86","author":"P Thapaliya","year":"2011","unstructured":"Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86(1):96\u20138. doi: 10.1002\/ajh.21892 .","journal-title":"Am J Hematol"},{"issue":"12","key":"178_CR28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","volume":"89","author":"A Martinez-Trillos","year":"2010","unstructured":"Martinez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Diaz-Beya M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol. 2010;89(12):1233\u20137.","journal-title":"Ann Hematol"},{"issue":"9","key":"178_CR29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"\u2022\u2022 Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398. doi: 10.1056\/NEJMoa1110556 . First randomized phase III trial of a JAK2 inhibitor vs. best available therapy in myelofibrosis.","journal-title":"N Engl J Med"},{"key":"178_CR30","doi-asserted-by":"crossref","unstructured":"Faoro L, Mesa R, Gertz MA, Tefferi A. Long-term analysis of the palliative benefit of 2-Chlorodeoxyadenosine (2-CdA) for myelofibrosis with myeloid metaplasia. Am J Clin Oncol. 2004.","DOI":"10.1111\/j.1600-0609.2004.00370.x"},{"issue":"2","key":"178_CR31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361\u201370.","journal-title":"Cancer"},{"issue":"2","key":"178_CR32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","volume":"103","author":"MA Elliott","year":"1998","unstructured":"Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103(2):505\u201311.","journal-title":"Br J Haematol"},{"issue":"12","key":"178_CR33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New Engl J Med. 2010;363(12):1117\u201327. doi: 10.1056\/NEJMoa1002028 .","journal-title":"New Engl J Med"},{"issue":"6","key":"178_CR34","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","volume":"120","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202\u20139. doi: 10.1182\/blood-2012-02-414631 .","journal-title":"Blood"},{"key":"178_CR35","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1200\/jco.2013.31.15_suppl.7030","volume":"31","author":"H-M Kvasnicka","year":"2013","unstructured":"Kvasnicka H-M, Thiele J, Bueso-Ramos CE, Hou K, Cortes JE, Kantarjian HM. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol. 2013;31:7030.","journal-title":"J Clin Oncol"},{"issue":"9","key":"178_CR36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"\u2022\u2022 Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807. doi: 10.1056\/NEJMoa1110557 . First randomized trial of JAK2 inhibitor vs. placebo, demonstrating a survival advantage in myelofibrosis.","journal-title":"N Engl J Med"},{"issue":"10","key":"178_CR37","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285\u201392. doi: 10.1200\/JCO.2012.44.4489 .","journal-title":"J Clin Oncol"},{"key":"178_CR38","author":"CN Harrison","year":"2013","unstructured":"Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013. doi: 10.1111\/bjh.12375 .","journal-title":"Br J Haematol"},{"issue":"4","key":"178_CR39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013;161(4):508\u201316. doi: 10.1111\/bjh.12274 .","journal-title":"Br J Haematol"},{"key":"178_CR40","doi-asserted-by":"crossref","unstructured":"Vannucchi A, Cervantes F, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuitty M et al. Long-term outcomes from a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF): A 3-YEAR update of COMFORT-II. Haematologica. 2013; Suppl:a5828.","DOI":"10.1182\/blood.V120.21.801.801"},{"issue":"7","key":"178_CR41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789\u201396.","journal-title":"J Clin Oncol"},{"key":"178_CR42","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1200\/jco.2013.31.15_suppl.7109","volume":"31","author":"CHMJ Animesh Dev Pardanani","year":"2013","unstructured":"Animesh Dev Pardanani CHMJ, Gabrail NY, et al. Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF). J Clin Oncol. 2013;31:7109.","journal-title":"J Clin Oncol"},{"key":"178_CR43","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/jco.2011.29.15_suppl.6515","volume":"29","author":"HJOO Deeg","year":"2011","unstructured":"Deeg HJOO, Scott BL, et al. Phase II study of SB1518, an orally available novel Jak2 inhibitor, in patients with myelofibrosis. J Clin Oncol. 2011;29:6515.","journal-title":"J Clin Oncol"},{"issue":"21","key":"178_CR44","first-page":"282","volume":"118","author":"RS Komrokji","year":"2011","unstructured":"Komrokji RS, Wadleigh M, Seymour JF, Roberts AW, To LB, Zhu HJ, et al. Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. ASH Ann Meet Abs. 2011;118(21):282.","journal-title":"ASH Ann Meet Abs"},{"issue":"6","key":"178_CR45","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322\u20137. doi: 10.1038\/leu.2013.71 .","journal-title":"Leukemia"},{"key":"178_CR46","doi-asserted-by":"crossref","unstructured":"Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H et al. Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. J Clin Oncol. 2009.","DOI":"10.1200\/JCO.2008.21.7356"},{"issue":"2","key":"178_CR47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","volume":"85","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, et al. Phase1\/-2 study of Pomalidomide in myelofibrosis. Am J Hematol. 2010;85(2):129\u201330. doi: 10.1002\/ajh.21598 .","journal-title":"Am J Hematol"},{"key":"178_CR48","author":"DJ Deangelo","year":"2013","unstructured":"Deangelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013. doi: 10.1111\/bjh.12384 .","journal-title":"Br J Haematol"},{"issue":"4","key":"178_CR49","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","volume":"150","author":"A Rambaldi","year":"2010","unstructured":"Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446\u201355. doi: 10.1111\/j.1365-2141.2010.08266.x .","journal-title":"Br J Haematol"},{"issue":"8","key":"178_CR50","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069\u201376. doi: 10.1182\/blood-2011-01-330563 .","journal-title":"Blood"},{"key":"178_CR51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/asheducation.V2012.1.553.3800163","volume":"2012","author":"SN Constantinescu","year":"2012","unstructured":"Constantinescu SN, Vainchenker W. Small-molecule inhibitors in myeloproliferative neoplasms: Are we aiming for the right targets? Hematol Am Soc Hematol Educ Program. 2012;2012:553\u201360. doi: 10.1182\/asheducation-2012.1.553 .","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0178-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-013-0178-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0178-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T13:11:45Z","timestamp":1716037905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-013-0178-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,8]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["178"],"URL":"https:\/\/doi.org\/10.1007\/s11899-013-0178-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,8]]}}}